PD-L1 antibody combined with CTLA-4 antibody (Shanghai Zhongshan Hospital)

N/A

Report date: 2023/03/05 16:37:35

Base Information

Drug NamePD-L1 antibody combined with CTLA-4 antibody (Shanghai Zhongshan Hospital)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionAnti-Programmed death-ligand 1Anti-CTLA4
TargetsProgrammed death-ligand 1Cytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsCholangiocarcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai Zhongshan Hospital
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Zhongshan Hospital
Inactive CompaniesN/A
Active IndicationsCholangiocarcinoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A